Interestingly, inhibition of IL-6 has been shown to attenuate AngII-induced cardiac hypertrophy and fibrosis32, and cardiac-deficiency of the NF-κB subunit, p65, led to reduced cardiac hypertrophy, and preserved contractile function after TAC33. Here, NFKB1 is linked to cardiac hypertrophy.